CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

October 5, 2026 · Phase 3 readout

GMAB Phase 3 readout: a positive outcome, +10.7%

On October 5, 2026, Epcoritamab — Genmab A/S (Diffuse Large B-Cell Lymphoma) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +10.7% in the window around the event.

The move

$34.75
1d before
$38.48
Event day
$37.80
1d after
$37.80
5d after

Pre-catalyst setup

+3.4%
30-day run-up
2570%
30-day volatility
2.1×
volume spike